Lingrui Pharma(SH:600285) Sou Hu Cai Jing·2025-08-19 13:09Core Viewpoint - Lingrui Pharmaceutical (SH600285) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential in the pharmaceutical sector [1]. Financial Performance - The company achieved an operating revenue of 2.099 billion yuan, representing a year-on-year growth of 10.14% [2]. - The net profit attributable to shareholders reached 474.39 million yuan, marking a 14.85% increase compared to the same period last year [2]. - The total profit for the period was 551.55 million yuan, which is a 15.12% increase from the previous year [2]. - The net cash flow from operating activities was 355.59 million yuan, reflecting a 22.36% increase year-on-year [2]. Asset and Equity Position - As of the end of the reporting period, the total assets amounted to 5.57 billion yuan, an increase of 11.07% from the previous year [2]. - The net assets attributable to shareholders were 3.07 billion yuan, showing a slight decrease of 0.20% compared to the end of the previous year [2]. Strategic Developments - During the reporting period, Lingrui Pharmaceutical completed the acquisition of 90% of Yingu Pharmaceutical, enhancing its presence in the external preparation field [2]. - Yingu Pharmaceutical contributed 98.78 million yuan in revenue and 13.23 million yuan in net profit, establishing a second growth curve for the company [2]. Leadership Compensation - The chairman and general manager, Xiong Wei, has seen a steady increase in annual salary, reaching 1.835 million yuan in 2024, which is significantly higher than the industry average [3][4].